Human Recombinant Insulin Market Analysis | CMI

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
HUMAN RECOMBINANT INSULIN MARKET ANALYSIS

• Human Recombinant Insulin Market, by Product Type
  (Rapid-Acting Human Insulin, Short-Acting Human
  Insulin, Intermediate-Acting Human Insulin,
  Long-Acting Human Insulin, and Premixed Human
  Insulin), by Brand (Humalog, Novolog, Apidra,
  Humulin R, Novolin R, Humulin N, Novolin N,
  Levemir, Lantus, Humalog Mix, Novolog Mix, and
  Others), By Distribution Channel (Hospital
  Pharmacies, Retail Pharmacies, and Online
  Pharmacies), and by Region - Global Forecast to
  2026
• The global human recombinant insulin market was
  valued at US 27.4 billion in 2018, and is
  expected to witness a CAGR of 7.2 over the
  forecast period (2018 2026).

3
Figure 1 Global Human Recombinant Insulin Market
Share, By Product Type
4
Market Drivers

• Increasing Investment in Diabetes Research
  Activities is expected to Boost the Growth of
  Human Recombinant Insulin Market
• Various government and private research
  organizations are engaged research and
  development activities for developing advanced
  treatment in diabetes care to increase the
  effectiveness of human insulin, reduce diabetes
  burden, and minimize the risk of diabetes
  associated disorders such as diabetes-associated
  blindness, kidney disease, heart attacks, strokes
  or limb loss. For instance, American Diabetes
  Association (ADA) invested US 807.4 million in
  more than 4,700 research projects in diabetes
  research since 1952 till 2017. According to ADA,
  2017 review, ADA invested more than US 37.4
  million for diabetes research in 2017, and
  supported 371 diabetes related research projects.
  The European Foundation for the Study of Diabetes
  (EFSD) a division of European Association for
  the Study of Diabetes (EASD), provides funding
  initiatives in all areas of diabetes research.
  EFSD aims to accelerates and support research in
  the field of diabetes to introduce innovative
  diabetic management portfolio.
• In September 2017, Biocon Limited an India-based
  biopharmaceutical firm received funding from
  Juvenile Diabetes Research Foundation (JDRF) to
  study oral insulin drug candidate Tregopil, to
  evaluate the safety and tolerability in people
  suffering with type 1 diabetes. The collaboration
  between Biocon and JDRF is a part of JDRF's
  Industry Discovery and Development Partnership
  (IDDP) programme, through which JDRF provides
  financial support to Biocon to accelerate
  research in type 1 diabetes management.

5

• Increasing Incidence of Diabetes Worldwide is
  expected to Drive Growth of the Human Recombinant
  Insulin Market
• Insulin plays a vital role in diabetes management
  by controlling blood sugar level. Both type 1 and
  type 2 diabetes people are benefited by
  maintaining blood sugar levels. Increasing
  incidence of diabetes is expected to be major
  factor driving growth of the market in the near
  future. For instance, according to the World
  Health Organization (WHO), 2016, an estimated 422
  million adults are suffering from diabetes. The
  major spike in incidence of type 2 diabetes over
  the last decade is mainly attributed to
  increasing prevalence of obesity. According to
  the International Diabetes Federation (IDF) Atlas
  2017, global burden of diabetes is affecting more
  than 425 million people, among which one-third
  are older than 65 years of age. Moreover, the
  number of people with diabetes may rise to 629
  million in 2045. Furthermore, 352 million with
  impaired glucose tolerance are at high risk of
  developing diabetes. Furthermore, continuous
  increase in incidence rate of diabetes, owing to
  unhealthy lifegt

6
Market Restraints

• However, high cost of insulin may restrain growth
  of the market, as patients from low and middle
  countries are unable to afford it. According to
  the Pharmaceutical Care Management Association
  (PCMA) May 2018 report, prices of insulin have
  increased over 10-fold since 1985 and prices have
  exhibited significant rise during the last past
  10 years (2008 to 2018). According to PCMA,
  prices for Humulin/Novolin have increased from
  around US 25 per prescription in 1985 to nearly
  US 300 in 2016. Furthermore, prices for
  long-acting insulins have increased from around
  US 100 per prescription in 2007 to nearly US
  400 in 2016.

7
Key Players

• Key players operating in human recombinant
  insulin market include Novo Nordisk A/S, Eli
  Lilly and Company, Sanofi S.A., Julphar Gulf
  Pharmaceutical Industries, Biocon Limited, Bioton
  S.A., Gan Lee Pharmaceuticals, Ltd., Zhuhai
  United Laboratories Co., Ltd., Wanbang
  Biopharmaceuticals Co., Ltd., and Dongbao
  Enterprise Group Co., Ltd.

8

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Reference https//www.coherentmarketinsights.com
  /market-insight/human-recombinant-insulin-market-1
  797

9
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

10
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

11

• Thank You!
• Kindly follow CMI Social Media Profiles
  for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/